期刊文献+

STAT3及XRCC4基因多态性与肝细胞癌易感性的关系研究 被引量:3

A case-control study on the relationship between polymorphisms of STAT3 and XRCC4 gene and the risk of hepatocellular carcinoma
下载PDF
导出
摘要 目的:探讨转录激活因子3(STAT3)及X线修复交叉互补基因4(XRCC4)基因多态性与中国人群肝细胞癌(HCC)易感性的关系。方法采用病例对照研究,以确诊的200例乙型肝炎病毒(HBV)感染相关 HCC 为肝癌组,207例性别及年龄匹配的 HBsAg阳性患者为非肝癌组。采用PCR-限制性长度多态性技术检测STAT3 rs2292152和XRCC4 rs1805377多态性位点的基因型,Logistic回归分析比较不同基因型与 HCC易感风险的关系。结果(1)STAT3 rs2293152位点3种基因型(CC、CG和GG型)在肝癌组分布频率分别为17%(34/200)、49.5%(99/200)和33.5%(67/200),在非肝癌组中分别为18.4%(38/207)、56.5%(117/207)和25.1%(52/207),各基因型在两组之间的差异无统计学意义(P>0.05);以CC基因型作参照,携带rs2293152 GG型的个体 HCC患病风险差异无统计学意义(OR=1.440,95% CI=0.800~2.592,P=0.224)。(2)XRCC4 rs1805377位点3种基因型(AA、GA和GG 型)在肝癌组分布频率分别为61%(122/200)、30%(60/200)和9%(18/200),在非肝癌组中分别为59.9%(124/207)、31.9%(66/207)和8.2%(17/207),各基因型在两组之间的差异无统计学意义(P>0.05);以 AA 基因型作参照,携带rs1805377 GG型的个体 HCC 患病风险差异无统计学意义(OR=1.076,95% CI=0.530~2.185,P=0.839)。结论 STAT3 rs2292152和XRCC4 rs1805377多态性位点可能与中国人群HBV 相关HCC 易感性无密切关系。 Objective To investigate the association of genetic polymorphisms of STAT3 and XRCC4 with susceptibility to hep- atocellular carcinoma (HCC) in Chinese population. Methods In this case-control study,a total of 200 HCC patients infected with hepatitis B virus (HBV) and 207 age-and gender-matched non-HCC controls infected with HBV were recruited. Genetic polymor- phisms of STAT3 rs2293152 and XRCC4 rs1805377 were genotyped using polymerase chain reaction combined with restriction fragment length polymorphism method (PCR-RFLP). Logistic regression model was used to analyze the relationship between dif- ferent genotypes and their susceptibility to HCC. Results (1) The frequencies of CC,CG and GG genotype on STAT3 rs2293152 were 17% (34/200),49.5X (99/200)and 33.5% (67/200) respectively in the HCC group,and 18.4%(38/207),56.5%(117/ 207) and 25.1% (52/207) respectively in non-HCC group,and there was no statistical significance (P〈0.05). Compared with CC genotype,rs2293152 GG genotype carriers showed no significant different in the susceptibility to HCC (OR 1. 440,95%CI=0. 800-2. 592,P=0. 224). (2) The frequencies of AA,GA and GG genotypes on XRCC4 rs1805377 were 61% (122/200) ,30% (60/ 200) and 9% (18/200) respectively in the HCC group,while 59.9% (124/207) ,31.9% (66/207) and 8.2% (17/207) respectively in non-HCC group, and there was no statistical significance (P〉0.05). Compared with AA genotype, rs1805377 C,G genotype carriers showed no significant different in the susceptibility to HCC (OR=1. 076,95%CI=0. 530-2. 185 ,P=0. 839). Conclusion The polymor- phisms of STAT 3 rs2293152 and XRCC4 rs1805377 were not closely associated with susceptibility to HCC in Chinese population.
出处 《国际检验医学杂志》 CAS 2014年第7期850-852,共3页 International Journal of Laboratory Medicine
基金 南京市第一层次卫生人才项目(2011024)
关键词 肝细胞癌 转录激活因子3 X线修复交叉互补基因4 单核苷酸多态性 signal TRANSDUCER and ACTIVATORS of TRANSCRIPTION 3 X-ray repair cross complementing group 4 hepatocellular carcinoma signal transducer and activators of transcription 3 X-ray repair cross complementing group 4 single nucleotide polymorphism
  • 相关文献

参考文献1

二级参考文献162

  • 1Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Statl activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998, 102:1385 - 1392.
  • 2Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcino-genesis in vivo. Proc Natl Acad Sci USA 2000, 97:4227-4232.
  • 3Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998,394:145- 151.
  • 4Gray M J, Zhang J, Ellis LM, et al. HIF- 1 alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005, 24:3110- 3120.
  • 5Loeffler S, Fayard B, Weis J, Weissenberger J. Intedeukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Spl. IntJ Cancer 2005,115:202-213.
  • 6Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol 2001, 28:56-66.
  • 7Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD 1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005,113:109-115.
  • 8Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Group ECO. Phase III randomized trial ofcisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005, 23:8646-8654.
  • 9Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 2005, 5:1085-1093.
  • 10Vincent PW, Bridges A J, Dykes D J, et al. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts. Cancer ChemotherPharmacol 2000, 45:231-238.

共引文献71

同被引文献78

  • 1O'Driscoll M.Diseases associated with defective responses to DNA damage[J].Cold Spring Harb Perspect Biol,2012,4(12):a012773.
  • 2Lema?tre C,Soutoglou E.DSB(Im)mobility and DNA repair compartmentalization in mammalian cells[J].J Mol Biol,2015,427(3)652-658.
  • 3Kurosawa A,Saito S,So S,Hashimoto M,Iwabuchi K,Watabe H,et al.DNA ligaseⅣand artemis act cooperatively to suppress homologous recombination in human cells:implications for DNA double-strand break repair[J].Plos One,2013,8(8):e72253.
  • 4Davis AJ,Chen BP,Chen DJ.DNA-PK:a dynamic enzyme in a versatile DSB repair pathway[J].DNA Repair(Amst),2014,17:21-29.
  • 5Ahmed EA,Sfeir A,Takai H,Scherthan H.Ku70and non-homologous end joining protect testicular cells from DNA damage[J].J Cell Sci,2013,126(14):3095-3104.
  • 6Imamichi S,Sharma MK,Kamdar RP,Fukuchi M,Matsumoto Y.Ionizing radiation-induced XRCC4phosphorylation is mediated through ATM in addition to DNA-PK[J].Proc Jpn Acad Ser B Phys Biol Sci,2014,90(9):365-372.
  • 7Dobbs TA,Tainer JA,Lees-Miller SP.A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation[J].DNA Repair(Amst),2010,9(12):1307-1314.
  • 8Urushihara Y,Kobayashi J,Matsumoto Y,Komatsu K,Oda S,Mitani H.DNA-PK inhibition causes a low level of H2AX phosphorylation and homologous recombination repair in Medaka(Oryzias latipes)cells[J].Biochem Biophys Res Commun,2012,429(3):131-136.
  • 9Ochi T,Wu Q,Blundell TL.The spatial organization of non-homologous end joining:from bridging to end joining[J].DNA Repair(Amst),2014,17(100):98-109].
  • 10Reiling E,DolléME,Youssef SA,Lee M,Nagarajah B,Roodbergen M,et al.The progeroid phenotype of Ku80 deficiency is dominant over DNAPKCS deficiency[J].PLo S One,2014,9(4):e93568.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部